Cargando…

Effects of Evolocumab on the ApoA1 Remnant Ratio: A Pooled Analysis of Phase 3 Studies

INTRODUCTION: The apolipoprotein A1 (apoA1) remnant ratio has been identified as an independent cardiovascular (CV) risk factor. Higher apoA1 remnant ratios may predict lower CV risk in some patients. This analysis aimed to evaluate the effects of evolocumab on the change from baseline in the apoA1...

Descripción completa

Detalles Bibliográficos
Autores principales:	May, Heidi T., Muhlestein, Joseph B., Ma, Yuhui, López, J. Antonio G., Coll, Blai, Nelson, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6525215/ https://www.ncbi.nlm.nih.gov/pubmed/30852766 http://dx.doi.org/10.1007/s40119-019-0133-6

Ejemplares similares

A new ratio for better predicting future death/myocardial infarction than standard lipid measurements in women >50 years undergoing coronary angiography: the apolipoprotein A1 remnant ratio (Apo A1/ [VLDL(3)+IDL])
por: May, Heidi T, et al.
Publicado: (2013)

HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis
por: Chyu, Kuang-Yuh, et al.
Publicado: (2015)

Serum Levels of ApoA1 and ApoA2 Are Associated with Cognitive Status in Older Men
por: Ma, Cheng, et al.
Publicado: (2015)

Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB/apoA-1 ratio—Experience from the Swedish AMORIS cohort: A cohort study
por: Walldius, Göran, et al.
Publicado: (2021)

Different Functional and Structural Characteristics between ApoA-I and ApoA-4 in Lipid-Free and Reconstituted HDL State: ApoA-4 Showed Less Anti-Atherogenic Activity
por: Yoo, Jeong-Ah, et al.
Publicado: (2015)

SIDT2 Associates with Apolipoprotein A1 (ApoA1) and Facilitates ApoA1 Secretion in Hepatocytes
por: Sampieri, Alicia, et al.
Publicado: (2023)

ApoA-1 in Diabetes: Damaged Goods
por: Ory, Daniel S., et al.
Publicado: (2010)

Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent
por: Lebherz, Corinna, et al.
Publicado: (2007)

Elevated ApoB/ApoA-I ratio is associated with acute anti-N-Methyl-D-aspartate receptor encephalitis, but not disease outcomes
por: Liu, Yingying, et al.
Publicado: (2022)

ApoA-I mimetic administration, but not increased apoA-I-containing HDL, inhibits tumour growth in a mouse model of inherited breast cancer
por: Cedó, Lídia, et al.
Publicado: (2016)

ApoB/ApoA-1 Ratio as a Novel Prognostic Predictor in Patients With Primary Small Cell Carcinoma of the Esophagus
por: Chen, Hao, et al.
Publicado: (2020)

The relation between ApoB/ApoA-1 ratio and the severity of coronary artery disease in patients with acute coronary syndrome
por: Yaseen, Rehab Ibrahim, et al.
Publicado: (2021)

Brain ApoA-I, ApoJ and ApoE Immunodetection in Cerebral Amyloid Angiopathy
por: Camacho, Jessica, et al.
Publicado: (2019)

Consistent LDL‐C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies
por: Stroes, Erik, et al.
Publicado: (2018)

The unsolved mystery of apoA-I recycling in adipocyte
por: Wang, Shuai, et al.
Publicado: (2016)

Leptin and adiponectin in relation to body fat percentage, waist to hip ratio and the apoB/apoA1 ratio in Asian Indian and Caucasian men and women
por: Smith, Jessica, et al.
Publicado: (2006)

LCAT, ApoD, and ApoA1 Expression and Review of Cholesterol Deposition in the Cornea
por: Flores, Rhonda, et al.
Publicado: (2019)

Effect of Evolocumab on Non‐High‐Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies
por: Toth, Peter P., et al.
Publicado: (2020)

Autophagy Alteration in ApoA-I Related Systemic Amyloidosis
por: Del Giudice, Rita, et al.
Publicado: (2022)

Comparison of Apolipoprotein (apoB/apoA-I) and Lipoprotein (Total Cholesterol/HDL) Ratio Determinants. Focus on Obesity, Diet and Alcohol Intake
por: Tognon, Gianluca, et al.
Publicado: (2012)

Effects of Individual Amino Acids on PPARα Transactivation, mTORC1 Activation, ApoA-I Transcription and pro-ApoA-I Secretion
por: Tayyeb, Jehad Z., et al.
Publicado: (2022)

The ratio of HDL-C to apoA-I interacts with free triiodothyronine to modulate coronary artery disease risk
por: Li, Li, et al.
Publicado: (2021)

Effect of apoA-I on cholesterol release and apoE secretion in human mature adipocytes
por: Bencharif, Karima, et al.
Publicado: (2010)

Human apoA-I[Lys107del] mutation affects lipid surface behavior of apoA-I and its ability to form large nascent HDL
por: Gorshkova, Irina N., et al.
Publicado: (2022)

ApoB/ApoA-I ratio is independently associated with carotid atherosclerosis in type 2 diabetes mellitus with well-controlled LDL cholesterol levels
por: Jun, Ji Eun, et al.
Publicado: (2018)

Obesity contributes more to increasing ApoB/ApoA1 ratio than hyperandrogenism in PCOS women aged 20–38 years in China
por: Zheng, Jianhua, et al.
Publicado: (2017)

High ApoB/ApoA-I Ratio Predicts Post-Stroke Cognitive Impairment in Acute Ischemic Stroke Patients with Large Artery Atherosclerosis
por: Lee, Minwoo, et al.
Publicado: (2023)

HDL-apoA-I Exchange: Rapid Detection and Association with Atherosclerosis
por: Borja, Mark S., et al.
Publicado: (2013)

Apolipoprotein A-I (ApoA-I), Immunity, Inflammation and Cancer
por: Georgila, Konstantina, et al.
Publicado: (2019)

Clinical ApoA‐IV amyloid is associated with fibrillogenic signal sequence
por: Canetti, Diana, et al.
Publicado: (2021)

Crystallization of ApoA1 and ApoE4 nanolipoprotein particles and initial XFEL-based structural studies
por: Shelby, M.L., et al.
Publicado: (2020)

ApoB/apoA1 is an effective predictor of coronary heart disease risk in overweight and obesity()
por: Lu, Min, et al.
Publicado: (2011)

Current and Emerging Reconstituted HDL-apoA-I and HDL-apoE Approaches to Treat Atherosclerosis
por: Valanti, Eftaxia-Konstantina, et al.
Publicado: (2018)

apoB/apoA‐I Ratio and Lp(a) Associations With Aortic Valve Stenosis Incidence: Insights From the EPIC‐Norfolk Prospective Population Study
por: Zheng, Kang H., et al.
Publicado: (2019)

Preprocedural Lp(a) level and ApoB/ApoA-Ι ratio and the risk for contrast-induced acute kidney injury in patients undergoing emergency PCI
por: Tao, Jun, et al.
Publicado: (2021)

A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies
por: Koren, Michael J., et al.
Publicado: (2020)

Elevated ApoB/apoA-1 is Associated with in-Hospital Mortality in Elderly Patients with Acute Myocardial Infarction
por: Chen, Yan, et al.
Publicado: (2023)

HDL-C/apoA-I Ratio Is Associated with the Severity of Coronary Artery Stenosis in Diabetic Patients with Acute Coronary Syndrome
por: Sun, Lizhe, et al.
Publicado: (2021)

No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab
por: Korthauer, Laura E., et al.
Publicado: (2022)

Is the ratio of apoB/apoA-1 the best predictor for the severity of coronary artery lesions in Chinese diabetics with stable angina pectoris? An assessment based on Gensini scores
por: Hong, Li-Feng, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_m0dr0jeui3d30lfj2pb2bfvpb1